Search results
Author(s):
Juxerez Maria B Sulit
,
Armand Delo Tan
Added:
1 month ago
Author(s):
Dharmaraj Karthikesan
,
Mohd Ridzuan Mohd Said
,
Chin Yung Chea
,
et al
Added:
4 months ago
Author(s):
Vivek Reddy
Added:
1 year ago
EHRA 24 - We interview Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, US) on a first-in-human clinical trial of a novel conformable "single-shot" pulsed field ablation (PFA) catheter for pulmonary vein isolation (PVI).This single arm trial aimed to assess the safety and efficacy of PVI using an 8Fr PFA catheter (SpherePVI, Affera Inc) in 30 patients across three centers.Interview…
View more
Author(s):
Kenneth Ellenbogen
Added:
6 months ago
A new policy statement released by HRS underscores the importance of continual training and education for electrophysiologists performing catheter ablation of atrial fibrillation (AF).In this short interview, Dr Kenneth Ellenbogen (VCU School of Medicine, US) discusses the key recommendations within this policy statement to ensure a strong electrophysiology base and skillset to achieve the best…
View more
Author(s):
Hartika Safitri
,
Amir Aziz Alkatiri
,
Doni Firman
,
et al
Added:
1 year ago
Author(s):
Khung Keong Yeo
,
Ryuji Fukazawa
,
Mamoru Ayusawa
,
et al
Added:
1 year ago
Author(s):
Yury Malyshev
Added:
1 year ago
AF Symposium 24 — Dr Yury Malyshev (Mount Sinai Hospital, US) joins us to discuss the findings from three studies focusing on the long-term effects of pulsed-field ablation (PFA) on coronary arteries.QuestionsWhat is known currently about the effect of PFA in Coronary Arteries? What is the importance of this topic?What was the study design and cohort?What are the key findings?Who are the take…
View more
Author(s):
Yi Hua Low
,
Gerald Gui Ren Sng
,
Samuel Ji Quan Koh
,
et al
Added:
2 years ago
Author(s):
Guzel Bikbaeva
,
Anna Kovalskaya
,
Alexander Rodin
,
et al
Added:
11 months ago
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more